Analysts Boost Centessa Pharmaceuticals plc (CNTA) Price Targets as Sleep Disorder Drug Shows Breakthrough Results

Centessa Pharmaceuticals plc (NASDAQ:CNTA) is one of the best 52-week high stocks to buy right now. On December 1, B. Riley boosted its price target on Centessa Pharmaceuticals plc (NASDAQ:CNTA) to $42 from $33 and reiterated its Buy rating after impressive Phase 2 data for ORX750.

Analysts Boost Centessa Pharmaceuticals plc (CNTA) Price Targets as Sleep Disorder Drug Shows Breakthrough Results

The CRYSTAL-1 study showed strong wake-promoting effects at much lower doses than competing drugs, with meaningful benefits in narcolepsy type 2 and idiopathic hypersomnia: including an 87% drop in cataplexy episodes, and a clean safety profile. Analysts pointed to Centessa’s potential lead over other developers, rising investor support, and a growing market for orexin-based therapies, especially as the Alkermes-Avadel merger highlights momentum in the space ahead of expected launches starting in 2026.

Previously on November 18, analysts at Guggenheim lifted their price target of the stock to $43 from $28 while reiterating a Buy rating. The price target hike follows the company’s topline results from its ORX750 CRYSTAL-1 Phase 2a study. According to Guggenheim, Centessa remains well-positioned to advance ORX750 in pivotal trials following an equity financing that raised $619 million in pro forma cash. Development of the candidate drug could expand its addressable market by targeting neurodegenerative and neuropsychiatric disorders.

Centessa Pharmaceuticals plc (NASDAQ:CNTA) is a pharmaceutical company that discovers and develops transformational medicines for patients with high unmet needs. Its key programs include a hemophilia program, an orexin agonist program for sleep-wake disorders like narcolepsy, and an immune-oncology program.

READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.

This article is originally published at Insider Monkey.